How did Concord Biotech's FY26 profitability compare to the prior year?

Consolidated net profit fell 30% year-on-year to ₹259.23 crore for the year ended March 31, 2026.

What was the top-line performance?

Revenue from operations contracted by 12% to ₹1,054.89 crore over the full fiscal year.

Did the company return cash to shareholders?

The board recommended a final dividend of ₹7.55 per equity share alongside the annual results.

What other board-level changes were made?

The company confirmed the five-year appointment of Ekta Gupta as an independent director and named new internal and cost auditors for FY27.

Earnings · Pharmaceuticals · Mid cap

Concord Biotech profit falls 30% on a 12% revenue slide

The Ahmedabad drug maker's annual results confirm a tough fiscal year, with net profit at ₹259.23 cr and revenue at ₹1,054.89 cr. The board still declared a dividend.

— 2 earlier stories on Concord Biotech Ltd. →

CONCORDBIO By Tipsheet Editorial 29 May 2026 · 8:39 PM IST Verify on BSE · NSE

Mkt cap₹10,997 cr

P/E35.19×

ROE20.50%

Debt / eq.0.00

Div yld1.02%

₹259.23 cr Consolidated net profit for FY26, down 30% year-on-year.

What's new

FY26 consolidated net profit fell 30% YoY to ₹259.23 crore.
Annual revenue from operations contracted by 12% to ₹1,054.89 crore.
Board recommended a final dividend of ₹7.55 per share and appointed new auditors.

Why this matters

The numbers confirm operational headwinds. A 12% revenue contraction with a steeper 30% profit drop points to significant margin pressure. The dividend is a modest concession to shareholders, but it doesn't offset the core earnings story.

What we're watching

Management commentary on the specific causes of the revenue and margin decline.
FY27 guidance, if any, in the subsequent concall.
Whether the new auditors flag any qualifications in their report.

The full read

Concord Biotech's FY26 results are a clean miss. The Ahmedabad drug maker reported a 30% year-on-year drop in consolidated net profit to ₹259.23 crore as annual revenue from operations contracted 12% to ₹1,054.89 crore. The profit decline outpacing the revenue fall suggests the company faced significant margin pressure. The board recommended a final dividend of ₹7.55 per share, a small return amid the earnings slide. Governance moves were routine: Ekta Gupta secured a five-year term as independent director, and new auditors were named for FY27. The audited numbers are now the hard baseline for the valuation conversation.

Questions answered

How did Concord Biotech's FY26 profitability compare to the prior year?: Consolidated net profit fell 30% year-on-year to ₹259.23 crore for the year ended March 31, 2026.
What was the top-line performance?: Revenue from operations contracted by 12% to ₹1,054.89 crore over the full fiscal year.
Did the company return cash to shareholders?: The board recommended a final dividend of ₹7.55 per equity share alongside the annual results.
What other board-level changes were made?: The company confirmed the five-year appointment of Ekta Gupta as an independent director and named new internal and cost auditors for FY27.

Mentioned: ₹259.23 cr net profit · ₹1,054.89 cr revenue · ₹7.55 dividend

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on CONCORDBIO →

29 May 2026 · 8:39 PM IST Concord Biotech profit falls 30% on a 12% revenue slide
1d ago Concord Biotech profit falls 30% as revenue contracts 11%
1d ago Concord Biotech profit drops 30% as revenue contracts for the year